
Indian Finance Minister Issues Warnings Regarding Crypto
The Indian finance minister suggested against using cryptocurrency.The law enforcement organization blocked the assets of two crypto exchanges.At a BJP Economic Cell event on Saturday,...
The Indian finance minister suggested against using cryptocurrency.The law enforcement organization blocked the assets of two crypto exchanges.At a BJP Economic Cell event on Saturday,...
(Bloomberg) -- Europe’s benchmark power price rose to a record for a fifth consecutive trading session as there are no signs of the natural gas rally slowing down. German year-ahead power...
Nov 13 (Reuters) - SMS Lifesciences India Ltd SMSL.NS :* SEPT-QUARTER CONSOL NET PROFIT 33.1 MILLION RUPEES VERSUS 36.8 MILLION RUPEES YEAR AGO* SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS...
Aug 21 (Reuters) - SMS Lifesciences India Ltd SMSL.NS :* JUNE QUARTER CONSOL NET PAT 24.8 MILLION RUPEES VERSUS 47.2 MILLION RUPEES YEAR AGO* JUNE QUARTER CONSOL REVENUE FROM OPERATIONS...
July 27 (Reuters) - SMS Lifesciences India Ltd SMSL.NS :* MARCH-QUARTER CONSOL NET PROFIT 15.7 MILLION RUPEES VERSUS 46 MILLION RUPEES YEAR AGO* MARCH-QUARTER CONSOL REVENUE FROM...
April 9 (Reuters) - SMS Lifesciences India Ltd SMSL.NS :* UPDATE ON RANITIDINE HCL* RANITIDINE HCL OCCUPIES MAJOR CONTRIBUTION IN ASPECT OF BOTH "VOLUMES AS WELL AS VALUE" FOR CO* CO DOES...
Feb 14 (Reuters) - SMS Lifesciences India Ltd SMSL.NS :* DEC QUARTER NET LOSS 2.9 MILLION RUPEES VERSUS PROFIT 51 MILLION RUPEES YEAR AGO* DEC QUARTER REVENUE FROM OPERATIONS 464 MILLION...
Nov 14 (Reuters) - SMS Lifesciences India Ltd SMSL.NS :* SEPT-QUARTER NET PROFIT 34.9 MILLION RUPEES VERSUS 44.1 MILLION RUPEES YEAR AGO* SEPT-QUARTER REVENUE FROM OPERATIONS 715.6 MILLION...
Oct 10 (Reuters) - SMS Lifesciences India Ltd SMSL.NS :* PRELIMINARY ANALYSIS OF OUR RANITIDINE PRODUCT AND PROCESSES AND FOUND THAT THE NDMA IMPURITY IS IN TRACE LEVELS* THE NDMA IMPURITY...
Nov 13 (Reuters) - SMS Lifesciences India Ltd SMSL.NS :* SEPT QUARTER NET PROFIT 44.1 MILLION RUPEES VERSUS PROFIT 10.2 MILLION RUPEES YEAR AGO* SEPT QUARTER REVENUE FROM OPERATIONS 892...
Sept 17 (Reuters) - SMS Lifesciences India Ltd SMSL.NS :* FURTHER ACQUIRED 1 MILLION SHARES IN MAHI DRUGS, MAKING IT CO'S UNIT...
July 30 (Reuters) - SMS Lifesciences India Ltd SMSL.NS : * JUNE QUARTER NET PROFIT 30.7 MILLION RUPEES VERSUS PROFIT OF 10.4 MILLION RUPEES YEAR AGO * JUNE QUARTER REVENUE FROM...
Feb 23 (Reuters) - SMS Lifesciences India Ltd SMSL.NS :* SAYS APPROVED ACQUISITION OF MAHI DRUGS PRIVATE LIMITED...
Feb 8 (Reuters) - SMS Lifesciences India Ltd SMSL.NS :* BOARD DEFERRED ISSUE OF NON-CONVERTIBLE PREFERENCE SHARES OR NON-CONVERTIBLE DEBENTURES ON PREFERENTIAL BASIS...
Feb 5 (Reuters) - SMS Lifesciences India Ltd SMSL.NS :* DEC QUARTER NET PROFIT 24.8 MILLION RUPEES VERSUS 43.4 MILLION RUPEES YEAR AGO* DEC QUARTER REVENUE FROM OPERATIONS 664.8 MILLION...
Dec 13 (Reuters) - Sms Lifesciences India Ltd SMSL.NS : * SEPT QUARTER NET PROFIT 10.2 MILLION RUPEES VERSUS PROFIT 17.5 MILLION RUPEES YEAR AGO * SEPT QUARTER REVENUE FROM OPERATIONS...
Sept 13 (Reuters) - SMS Lifesciences India Ltd SMSL.NS* June quarter profit 10.4 million rupees versus profit of 46.9 million rupees year ago* June quarter revenue from operations 458.3...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.